TREATMENT
Study Evaluates Trifluridine/Tipiracil in MSI-H/dMMR Metastatic CRCA study across 10 Japanese hospitals aimed to evaluate trifluridine/tipiracil (with or without bevacizumab) in MSI-H/dMMR metastatic colorectal cancer, a population known to resist standard fluorouracil-based therapies. (Therapeutic Advances in Medical Oncology)